NASDAQ$TNYA

Tenaya Therapeutics Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Tenaya Therapeutics reported Q4 2024 a net loss of $23.8M.

For Q4 2024, Tenaya Therapeutics reported net loss was $23.8M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Net loss $23.8M.
  • MD&A highlights operating priorities, liquidity, and sector risks.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$0.00

Previous: $17.7M-100.0%
EPS (adj)

-$0.28

Previous: -$0.40+30.0%
Research and Development Expenses

$18.7M

Previous: $22.9M-18.3%
General and Administrative Expenses

$5.96M

Previous: $8.58M-30.5%
Net Loss Per Share, Basic and Diluted

-$0.28

Previous: -$0.40+30.0%
Total Operating Expenses

$24.7M

Previous: $31.4M-21.6%
Interest Income

$812K

Previous: $1.47M-44.8%
Other Income, Net

$4K

Previous: $41K-90.2%
Total Other Income, Net

$816K

Previous: $1.51M-46.0%
Net Loss Before Income Tax Expense

-$23.8M

Previous: -$29.9M+20.4%
Weighted-Average Shares Used in Computing Net Loss Per Share, Basic and Diluted

86.4M

Previous: 74.1M+16.6%
Capital Expenditures

-$204K

Previous: -$394K+48.2%
Net Income

-$23.8M

Previous: -$29.9M+20.5%
Operating Income

-$24.7M

Previous: -$31.4M+21.6%
Gross Profit

-$2.09M

Previous: $14.7M-114.2%
R&D Expense

$18.7M

Previous: $22.9M-18.3%

Revenue & EPS history

Tenaya Therapeutics · Revenue · Quarterly

$0

Q4 2024-100%vs Q4 2023
Beat estimate in 0 of 2 quarters(0%)
ActualEstimate

Forward guidance

Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.

Tailwinds

  • Pipeline progress and partnership economics.
  • Cash supports near-term operating plans.

Headwinds

  • Operating losses until commercial scale.
  • Financing and trial outcomes affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+2.8%

Avg return

Earnings day

+2.1%

Avg return

5 days after

-5.6%

Avg return

30 days after

50%

9 / 18 earnings

Positive

+39.8%

Q3 2022

Best reaction

-18.7%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.8%+30.3%-4.2%
Q4 2025-1.3%-0.2%-19.7%
Q3 2025-1.4%-7.0%-4.9%
Q1 2025+7.8%-3.3%+38.2%
Q4 2024-6.5%-12.7%-38.4%
Q3 2024+17.4%+20.7%+68.1%
Q1 2024-0.7%+8.9%-12.6%
Q4 2023-8.9%-5.1%-13.6%
Q3 2023-7.8%-10.2%-2.9%
Q2 2023+7.3%+0.0%-24.6%
Q1 2023+12.1%+7.2%+9.0%
Q4 2022-18.7%-20.6%-25.9%
Q3 2022+39.8%+53.4%+11.0%
Q2 2022+1.5%+6.5%-11.3%
Q1 2022-5.7%-6.7%-29.9%
Q4 2021+6.0%+3.2%-5.0%
Q3 2021+7.7%-13.5%-28.1%
Q2 2021-2.8%-12.6%-6.5%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro